Baldi, GG, Giani, C, Ljevar, S, Denu, RA, Napolitano, A, Han, I, Brunello, A, Bhadri, V, Sebio, A, Andelkovic, V, Campos, F, Scanferla, R, Abreu, MH, Desar, IME, Ogura, K, Wong, DD, Bae, S, Bakhshi, S, Lefler, DS, Marquina, G, Mazzocca, A, Nakazawa, MS, Thway, K, Kim, HS, Chiusole, B, Connolly, EA, Terés, R, Antonescu, C, Bellan, E, Bovee, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Gronchi, A, Miceli, R, Chen, TW, Stacchiotti, S. Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium. EUROPEAN JOURNAL OF CANCER. 2026; 238DOI:10.1016/j.ejca.2026.116666. PMID:41819027. IF:7.100(Q1/2D).

Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).

Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).

Sierra-Rodero, B, Gil-González, A, Molina-Alejandre, M, Nadal, E, Calvo, V, Lázaro, M, Insa, A, Massuti, B, Marti, AM, de Castro, J, Campelo, RG, Larriba, JLG, Bernabé, R, Dómine, M, Aix, SP, Cobo, M, Camps, C, Reguart, N, Bosch-Barrera, J, Majem, M, Aguilar, A, Palmero, R, Clemente, MB, Martín-López, J, Muñoz-Viana, R, Megías, D, Gutiérrez-Escobedo, JM, Martínez-Toledo, C, Cruz-Bermúdez, A, Provencio, M. Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2026; 32(8)DOI:10.1158/1078-0432.CCR-25-3315. PMID:41805895. IF:10.200(Q1/1D).

Gillessen, S, Gallardo, E, Choudhury, A, Saad, F, Soares, A, Loriot, Y, McDermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, da Trindade, KM, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Tombal, B. Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. ANNALS OF ONCOLOGY. 2026; 37(5)DOI:10.1016/j.annonc.2026.02.009. PMID:41763609. IF:65.400(Q1/1D).

Yaringaño, J, Mirallas, O, Navarro, V, Gómez-Puerto, D, Velilla, G, Vaz, MA, Gorria, T, Martínez-Monino, A, Hernández, A, Aguado, M, Di Muzio, A, Valbuena, DL, Ruiz-Pace, F, González, M, Martínez-García, M, Villacampa, G, Balaña, C, Carles, J, Dienstmann, R, Pineda, E, Sepúlveda, JM, Vieito, M. Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort. Cancer Medicine. 2026; 15(4)DOI:10.1002/cam4.71825. PMID:42002922. IF:3.100(Q2/5D).

Gámez-Pozo, A, Trilla-Fuertes, L, Becerril-Gómez, F, Lalanda-Delgado, P, Soriano, V, Goldaraz, FG, Lecumberri, MJ, de la Borbolla, MR, Majem, M, Pérez-Ruiz, E, González-Cao, M, Oramas, J, López-Vacas, R, Magdaleno, A, Fra, J, Martín-Carnicero, A, Corral, M, Puértolas, T, Ramos-Ruiz, R, Espinosa, E, Vara, JAF. Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; 75(5)DOI:10.1007/s00262-026-04392-1. PMID:42047827. IF:5.100(Q1/3D).

Herrera, IC, Cols, LC, Pijuan-Andujar, L, Cajo, SA, Montalvan, RG, Calvente, MG, Luque, GA, Gallardo, A, Jaramillo, JFC. Impact of Cell-Free TNA Fraction on Analytical Success in Liquid Biopsy for Lung Adenocarcinoma: Experience from a Tertiary Hospital. LABORATORY INVESTIGATION. 2026; 106(3)DOI:10.1016/j.labinv.2025.105990. PMID:. IF:4.200(Q1/1D).